Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC

BACKGROUND: The anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-TKIs) have been administered to patients with ALK-positive non-small cell lung cancer for a long period of time and show a promising response. However, the differences in the toxicity profiles among these drugs are still uncl...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Qian, Hu, Hao, Weng, De-Sheng, Zhang, Xiao-Fei, Chen, Chang-Long, Zhou, Zi-Qi, Tang, Yan, Xia, Jian-Chuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5469041/
https://www.ncbi.nlm.nih.gov/pubmed/28606126
http://dx.doi.org/10.1186/s12885-017-3405-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5469041/
https://www.ncbi.nlm.nih.gov/pubmed/28606126
http://dx.doi.org/10.1186/s12885-017-3405-3

Ejemplares similares